Progress in the treatment of chronic lymphocytic leukemia (CLL).
| Study . | Treatment . | n . | CR, % . | OR, % . | PFS, mos . | Reference . |
|---|---|---|---|---|---|---|
| Abbreviations: CR, complete response; OR, overall response; PFS, progression-free survival; CALGB, Cancer and Leukemia Group B; GCLLSG, German CLL study group; ECOG, Eastern Cooperative Oncology Group; LRF, Leukaemia Research Fund; MDACC, MD Anderson Cancer Center | ||||||
| CALGB 9011 | Chlorambucil | 181 | 4 | 37 | 14 | Rai et al42 |
| Fludarabine | 170 | 20 | 63 | 20 | ||
| GCLLSG CLL4 | Fludarabine | 180 | 7 | 83 | 20 | Eichhorst et al43 |
| Fludarabine/cyclophosphamide | 182 | 24 | 94 | 48 | ||
| ECOG E2997 | Fludarabine | 137 | 5 | 59 | 19 | Flinn et al44 |
| Fludarabine/cyclophosphamide | 141 | 23 | 74 | 32 | ||
| LRF CLL4 | Chlorambucil | 366 | 7 | 72 | 20 | Catovsky et al40 |
| Fludarabine | 181 | 15 | 80 | 23 | ||
| Fludarabine/cyclophosphamide | 182 | 38 | 92 | 43 | ||
| MDACC Phase II | Rituximab/fludarabine/ cyclophosphamide | 224 | 72 | 95 | 80 | Tam et al45 |
| GCLLSG CLL8 | Fludarabine/cyclophosphamide Rituximab/fludarabine/ cyclophosphamide (RFC) | 817 recruited to both arms | ? | ? | Significantly prolonged in RFC arm | |
| Study . | Treatment . | n . | CR, % . | OR, % . | PFS, mos . | Reference . |
|---|---|---|---|---|---|---|
| Abbreviations: CR, complete response; OR, overall response; PFS, progression-free survival; CALGB, Cancer and Leukemia Group B; GCLLSG, German CLL study group; ECOG, Eastern Cooperative Oncology Group; LRF, Leukaemia Research Fund; MDACC, MD Anderson Cancer Center | ||||||
| CALGB 9011 | Chlorambucil | 181 | 4 | 37 | 14 | Rai et al42 |
| Fludarabine | 170 | 20 | 63 | 20 | ||
| GCLLSG CLL4 | Fludarabine | 180 | 7 | 83 | 20 | Eichhorst et al43 |
| Fludarabine/cyclophosphamide | 182 | 24 | 94 | 48 | ||
| ECOG E2997 | Fludarabine | 137 | 5 | 59 | 19 | Flinn et al44 |
| Fludarabine/cyclophosphamide | 141 | 23 | 74 | 32 | ||
| LRF CLL4 | Chlorambucil | 366 | 7 | 72 | 20 | Catovsky et al40 |
| Fludarabine | 181 | 15 | 80 | 23 | ||
| Fludarabine/cyclophosphamide | 182 | 38 | 92 | 43 | ||
| MDACC Phase II | Rituximab/fludarabine/ cyclophosphamide | 224 | 72 | 95 | 80 | Tam et al45 |
| GCLLSG CLL8 | Fludarabine/cyclophosphamide Rituximab/fludarabine/ cyclophosphamide (RFC) | 817 recruited to both arms | ? | ? | Significantly prolonged in RFC arm | |